{"id":38790,"date":"2025-08-07T14:39:25","date_gmt":"2025-08-07T06:39:25","guid":{"rendered":"https:\/\/flcube.com\/?p=38790"},"modified":"2025-08-07T14:39:26","modified_gmt":"2025-08-07T06:39:26","slug":"neowise-biotechnologys-nw-101c-receives-nmpa-clinical-trial-approval-for-prame-targeted-tcr-t-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38790","title":{"rendered":"Neowise Biotechnology&#8217;s NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy"},"content":{"rendered":"\n<p>China-based Neowise Biotechnology (Suzhou) Co., Ltd. announced that its self-developed PRAME-targeting autologous TCR-T cell therapy candidate, NW-101C injection, has received implied clinical trial approval from China&#8217;s National Medical Products Administration (NMPA). This marks the company&#8217;s first product to enter registration clinical trials and represents the first PRAME-targeting TCR-T cell therapy in China to advance into clinical research.<\/p>\n\n\n\n<p><strong>Product Profile<\/strong><br>NW-101C injection targets the tumor antigen PRAME, which is highly and specifically expressed in various solid tumors while being largely absent in normal tissues. This selective targeting enhances the therapy&#8217;s potential to effectively combat cancer cells while minimizing impact on healthy tissues.<\/p>\n\n\n\n<p><strong>Preclinical Results<\/strong><br>In preclinical studies, NW-101C demonstrated robust anti-tumor activity and a favorable safety profile. The approved indications include patients with HLA-A*02:01-positive, PRAME-expressing, unresectable recurrent or metastatic advanced malignant solid tumors. Specific conditions covered are ovarian cancer, malignant melanoma, esophageal squamous cell carcinoma, lung squamous cell carcinoma, soft tissue sarcoma, and triple-negative breast cancer.<\/p>\n\n\n\n<p><strong>Company Overview<\/strong><br>Neowise Biotechnology is an innovative company dedicated to developing TCR-T immunocell therapies for solid tumors. The company has established a high-throughput, high-sensitivity target antigen-TCR discovery platform. With multiple clinical-stage pipelines, Neowise has observed positive efficacy and good safety in several trials, positioning itself as a promising player in the field of cancer immunotherapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Neowise Biotechnology (Suzhou) Co., Ltd. announced that its self-developed PRAME-targeting autologous TCR-T cell therapy&#8230;<\/p>\n","protected":false},"author":1,"featured_media":38791,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,3075],"class_list":["post-38790","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-neowise-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Neowise Biotechnology&#039;s NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Neowise Biotechnology (Suzhou) Co., Ltd. announced that its self-developed PRAME-targeting autologous TCR-T cell therapy candidate, NW-101C injection, has received implied clinical trial approval from China&#039;s National Medical Products Administration (NMPA). This marks the company&#039;s first product to enter registration clinical trials and represents the first PRAME-targeting TCR-T cell therapy in China to advance into clinical research.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38790\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neowise Biotechnology&#039;s NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy\" \/>\n<meta property=\"og:description\" content=\"China-based Neowise Biotechnology (Suzhou) Co., Ltd. announced that its self-developed PRAME-targeting autologous TCR-T cell therapy candidate, NW-101C injection, has received implied clinical trial approval from China&#039;s National Medical Products Administration (NMPA). This marks the company&#039;s first product to enter registration clinical trials and represents the first PRAME-targeting TCR-T cell therapy in China to advance into clinical research.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38790\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-07T06:39:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-07T06:39:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0710.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38790#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38790\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Neowise Biotechnology&#8217;s NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy\",\"datePublished\":\"2025-08-07T06:39:25+00:00\",\"dateModified\":\"2025-08-07T06:39:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38790\"},\"wordCount\":235,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38790#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0710.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Neowise Biotechnology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38790#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38790\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38790\",\"name\":\"Neowise Biotechnology's NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38790#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38790#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0710.webp\",\"datePublished\":\"2025-08-07T06:39:25+00:00\",\"dateModified\":\"2025-08-07T06:39:26+00:00\",\"description\":\"China-based Neowise Biotechnology (Suzhou) Co., Ltd. announced that its self-developed PRAME-targeting autologous TCR-T cell therapy candidate, NW-101C injection, has received implied clinical trial approval from China's National Medical Products Administration (NMPA). This marks the company's first product to enter registration clinical trials and represents the first PRAME-targeting TCR-T cell therapy in China to advance into clinical research.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38790#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38790\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38790#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0710.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0710.webp\",\"width\":1080,\"height\":608,\"caption\":\"Neowise Biotechnology's NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38790#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neowise Biotechnology&#8217;s NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Neowise Biotechnology's NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Neowise Biotechnology (Suzhou) Co., Ltd. announced that its self-developed PRAME-targeting autologous TCR-T cell therapy candidate, NW-101C injection, has received implied clinical trial approval from China's National Medical Products Administration (NMPA). This marks the company's first product to enter registration clinical trials and represents the first PRAME-targeting TCR-T cell therapy in China to advance into clinical research.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38790","og_locale":"en_US","og_type":"article","og_title":"Neowise Biotechnology's NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy","og_description":"China-based Neowise Biotechnology (Suzhou) Co., Ltd. announced that its self-developed PRAME-targeting autologous TCR-T cell therapy candidate, NW-101C injection, has received implied clinical trial approval from China's National Medical Products Administration (NMPA). This marks the company's first product to enter registration clinical trials and represents the first PRAME-targeting TCR-T cell therapy in China to advance into clinical research.","og_url":"https:\/\/flcube.com\/?p=38790","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-07T06:39:25+00:00","article_modified_time":"2025-08-07T06:39:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0710.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38790#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38790"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Neowise Biotechnology&#8217;s NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy","datePublished":"2025-08-07T06:39:25+00:00","dateModified":"2025-08-07T06:39:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38790"},"wordCount":235,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38790#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0710.webp","keywords":["Cancer","Clinical trial approval \/ initiation","Neowise Biotechnology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38790#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38790","url":"https:\/\/flcube.com\/?p=38790","name":"Neowise Biotechnology's NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38790#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38790#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0710.webp","datePublished":"2025-08-07T06:39:25+00:00","dateModified":"2025-08-07T06:39:26+00:00","description":"China-based Neowise Biotechnology (Suzhou) Co., Ltd. announced that its self-developed PRAME-targeting autologous TCR-T cell therapy candidate, NW-101C injection, has received implied clinical trial approval from China's National Medical Products Administration (NMPA). This marks the company's first product to enter registration clinical trials and represents the first PRAME-targeting TCR-T cell therapy in China to advance into clinical research.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38790#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38790"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38790#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0710.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0710.webp","width":1080,"height":608,"caption":"Neowise Biotechnology's NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38790#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Neowise Biotechnology&#8217;s NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0710.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38790"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38790\/revisions"}],"predecessor-version":[{"id":38792,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38790\/revisions\/38792"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38791"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}